Mitigating Manufacturer Exposure to US MFN Policy
As US Most Favored Nation (MFN) drug pricing policy frameworks take shape, biopharmaceutical manufacturers face a new level of global pricing complexity. With proposed models such as GLOBE, GUARD and GENEROUS benchmarking US prices against international markets, the long-standing gap between US and European pricing is emerging as a critical risk to revenue and portfolio value.
This white paper provides a clear, strategic lens on how manufacturers can respond. It outlines practical, market-specific pathways to rebalance global pricing while maintaining compliance and access.
Drawing on real-world policy dynamics and country-level mechanisms, the paper explores how manufacturers can:
- Navigate evolving MFN policy models and their implications for global price benchmarking
- Identify assets most at risk of influencing US price floors
- Leverage established European repricing pathways, including cost-driven revisions, evidence-based reassessments and market sustainability arguments
- Apply a structured prioritization framework based on feasibility and MFN exposure to guide action across portfolios
For biopharma leaders navigating uncertainty, this perspective offers actionable guidance to protect value, optimize pricing corridors and sustain market access in an MFN-driven landscape.
